戻る Agenda
Session 5A: Leveraging CDMOs to Optimize Biologics Product Development and Manufacturing Strategies
Session Chair(s)
Michael Jenkins, PhD
Senior Consultant
BioProcess Technology Consultants, Inc., United States
One of the strategic decisions that must be made during product development is how and where to develop and manufacture the product. Manufacturing in-house, partnering with a company with excess capacity, and working with a CMO are common options. This session focuses on advantages of working with CDMO that go beyond accessing capacity. A good CDMO has extensive expertise in areas such as cell line, process and method development QbD, continuous manufacturing, and accelerated development programs, and will apply this expertise as appropriate to optimize the long-term manufacturing strategy for their client. This session will discuss best practices in working with CDMOs.
Speaker(s)
Speaker
Jose Ochoa
IDT Biologika, United States
Chief Business Officer
Selecting a CDMO: Perspective from a Small Biopharma Company
Karen Cui, MD, PhD
Precision Biologics, Inc., United States
Head, Drug Development
Getting to Win-Win: Reflections from CMO and Client Perspectives
Manoj Menon, PhD
AstraZeneca, United States
Director, New Products, Biologics Global Technical Operations